ABVC BioPharma, Inc. (NASDAQ: ABVC) saw its shares advance 14.58% last Friday, closing at $2.75, after announcing the receipt of a significant milestone payment. The company confirmed a $100,000 payment from OncoX BioPharma, Inc., linked to a 2024 licensing agreement.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
With this addition, ABVC and its subsidiaries have now accumulated a total of $1,046,000 in licensing revenue from agreements with AiBtl, ForSeeCon, and OncoX.
Strengthening Strategic Partnership with OncoX
The payment builds on ABVC BioPharma’s ongoing collaboration with OncoX, emphasizing confidence in the joint effort’s potential to deliver innovative oncology solutions. This financial milestone not only underscores the commercial value of ABVC’s late-stage oncology platform but also supports initiatives aimed at expanding OncoX’s therapeutic portfolio and enhancing its market presence.
The partnership is actively working to advance botanical-based treatments for oncology, with development programs supported by strong preclinical efficacy data.
Commercialization Path and Revenue Potential
Under the terms of the licensing agreement, the collaboration encompasses global commercialization rights for botanical oncology therapeutics. Beyond the current payment, the agreement includes additional milestones and royalty-based revenue opportunities, reinforcing ABVC BioPharma’s long-term growth outlook.
The total disclosed potential value of licensing agreements exceeds $959 million, comprising approximately $667 million from AiBtl, $105 million from OncoX, and $187 million from ForSeeCon.
Financial Performance and Market Outlook
This latest milestone aligns with ABVC BioPharma’s 2025 guidance, supported by the company’s strong performance in the previous year. In 2024, ABVC recorded a 234% year-over-year increase in revenue and a 77% improvement in earnings per share.
These results reflect the growing market interest in the company’s differentiated drug development model. Management remains confident in the potential of its oncology pipeline, anticipating future regulatory submissions and commercialization milestones through its partnership with OncoX.
The sustained collaboration between ABVC and its partners positions the company to capitalize on expanding opportunities in botanical-based oncology therapeutics, reinforcing its strategic growth trajectory in global markets.
